Propylthiouracil is not metabolized by cyp-enzymes, nor does it induce or inhibit the activity of cyp-enzymes. Propylthiouracil has no potential porphyrogenic pharmacokinetic or pharmacodynamic properties.

Propylthiouracil is a thiourea anti thyroid drug. It inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine.

Propylthiouracil is used in the management of hyperthyroidism. It is usually administered orally.

Propylthiouracil undergoes rapid first-pass metabolism in the liver, and is mainly excreted in the urine as the glucuronic acid conjugate, with very little excreted as unchanged drug. It has an elimination half-life of 1-3 hours. Propylthiouracil is about 80% bound to plasma proteins. Propylthiouracil has no potential of pharmacokinetic drug interactions involving cyp-enzymes.

Uneventful use reported in 2 patients with acute porphyria.